Introduction
A hallmark of Hodgkin's disease (HD) is the appearance of the characteristic Hodgkin and Reed-Sternberg (H/RS) cells in an affected tissue. Recent data indicate that H/RS cells represent a clonal cell population derived in the majority of cases from B cell precursors within the germinal center. 1 Recently, two cases of classic HD with T cell markers and clonal T cell receptor ␥ rearrangements in H/RS cells have been identified, indicating that cases with T cell-derived H/RS cells appear at low frequency. 2 However, the transforming events in H/RS cells have still not been elucidated. The Epstein-Barr virus, which can immortalize B lymphocytes is frequently detected in HD. 3 Expression of interleukin-6 and interleukin-6 receptors has been detected in H/RS cells and IL-6 expression appears to be up-regulated in EBV-associated HD. 4, 5 In addition, the expression of various cellular oncogenes has been described in HD. [6] [7] [8] The significance of EBV infection and the role of distinct cytokines and oncogene- Activation of PI3-kinase is one of the immediate cellular responses after stimulation with growth factors and cytokines. 9 ,10 PI3-kinase phosphorylates the D3 position of the inositol ring of phosphatidylinositol (PI), PI(4)P and PI(4,5)P 2 , resulting in a rapid and transient increase mostly of PI(3,4,5)P 3 and PI(3,4)P 2 in stimulated cells.
11 These 3-phosphorylated lipids act directly as second messengers by recruiting cytoplasmic proteins with pleckstrin homology (PH) domains to the plasma membrane where they find their appropriate substrates. Two examples of such specific interactions mediated by PH domains have been recently demonstrated for members of the Tec family of non-receptor tyrosine kinases 12 and for the Ser/Thr-kinase Akt, which is also named protein kinase B. 13 The PI3-kinase/Akt signaling pathway has been implicated in the protection of hematopoietic cells and other cell types against apoptosis. [14] [15] [16] In addition to their involvement in the inhibition of apoptosis, PI3-kinase and Akt have a transforming potential, as indicated by the identification of viral oncogenic forms of PI3-kinase and Akt, ie v-p3k 17 and v-akt, 18 respectively. Transformation of hematopoietic cells by Bcr/Abl requires activation of a PI3-kinase/Akt signaling pathway, 19 and mutated forms of oncogenes that do not bind to and activate PI3-kinase can not transform cells.
20,21
The 85 kDa subunit (p85) of the heterodimeric p85/p110 PI3-kinase consists of an SH3 domain, a bcr-homologous region, two proline rich regions, and two SH2 domains (N-SH2 and C-SH2) separated by an inter-SH2 region which interacts with the catalytic p110 subunit. [22] [23] [24] [25] Two cDNAs encoding p85 subunits of PI3-kinase have been cloned and designated p85␣ and p85␤. 23 As a result of alternative splicing, two additional forms of p85 have been described which either lack the SH3 domain and bcr-homologous region, or have nine additional amino acids inserted between the SH2 domains. 26 One other gene with homology to p85 which can also regulate PI3-kinase activity has been cloned, and termed p55 PIK . 27 Several mechanisms by which p85 regulates PI3-kinase activity have been described. By using its SH2 domains, p85 can function as an adapter molecule that targets p110 to tyrosine-phosphorylated motifs within growth factor receptors. 28, 29 The src family of tyrosine kinases can bind with their SH3 domains to proline-rich sequences within the p85 subunit, thereby stimulating PI3-kinase activity. 30 An oncogenic form of the p85␣ subunit of PI3-kinase has been recently isolated from a murine thymic lymphoma after X-ray irradiation. 31 This mutated form of p85␣/PI3-kinase named p65/PI3-kinase is a C-terminal-truncated form of the p85␣ subunit which activates PI3-kinase and Akt and contributes to cellular transformation. 31 Both effects were due to deletion of the C-terminal SH2-domain of p85␣. 31 Transgenic mice expressing p65/PI3-kinase in T lymphocytes develop an infiltrating lymphoproliferative disorder and cooperate with defects in p53 in generating T cell lymphomas. 32 Here we describe the molecular cloning and biochemical characterization of p76␣/PI3-kinase, a C-terminal-truncated form of p85␣/PI3-kinase expressed in a human lymphoma cell line (CO) with a T cell phenotype derived from a patient with Hodgkin's disease. 39 were obtained from Dr H Tesch (University Hospital Cologne, Germany), and the human T cell line Jurkat was obtained from Dr A Guse (University of Hamburg). These cell lines were cultured in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% (vol/vol) fetal bovine serum. Peripheral blood mononuclear cells (PBMC) were obtained from healthy donors and from patients with acute myeloid leukemia after informed consent. The diagnosis in each case was made by morphology, cytochemistry and surface antigen analysis. PBMC were prepared by density gradient centrifugation using Histopaque-1077 according to the manufacturer (Sigma, Deisenhofen, Germany). Cells were treated with the PI3-kinase inhibitors wortmannin or LY294002 for various times at different concentrations, as indicated in the figure legends. It has been described that wortmannin is unstable in aqueous solutions at physiological pH 40 and that its inhibitory activity for PI3-kinase is reduced to 50% in approximately 1 h at 37°C in RPMI medium.
Materials and methods

Cells
14 Therefore we added wortmannin twice a day to overcome at least in part the problem of degradation. Control cultures received the same amount of ethanol, used as the solvent for wortmannin and LY294002. Apoptosis was analyzed by incubating the cells with annexin V (Oncogene, Boston, MA, USA) according to the manufacturer's protocol. The percentage of annexin V-positive cells were determined by flow cytometry using a FACScan from Becton Dickinson (San Jose, CA, USA).
Reverse transcriptase PCR
CO and DEV cells were lysed in guanidinium isothiocyanate buffer and RNA was purified by CsCl gradient centrifugation as described. 6 cDNA was prepared by reverse transcription of 5 g total RNA using 200 units Superscript-RT (Gibco BRL) with a specific antisense primer from a region immediately downstream of the 3Ј end of the coding region of p85␣/PI3-kinase (AGTAAGCGCTTCATCGCCTCTGCTGTGC). cDNAs encoding the N-terminal and C-terminal halves of p85␣ were amplified by using 35 cycles of PCR with two sets of primers, ie CAGATTTGCAAACATGAGTGCTGAG (5Ј-primer) and CAGAGAAGCCATATTTCCCATCTCG (3Ј-primer) for the Nterminal half, and TGGTACTGGGGAGATATCTCGAGGG AAG (5Ј-primer) and AGTAAGCGCTTCATCGCCTCTGCTG TGC (3Ј-primer) for the C-terminal half. The amplified PCR products were directly sequenced by the dideoxy sequencing method 41 and analyzed with an automated DNA sequence analyzer. The N-and C-terminal halves of p85 were fused together by ligation at the AccI site in p85␣.
Leukemia
Genomic PCR
To obtain genomic clones of p85␣ including the C-terminal SH2-domain from CO and DEV cells we isolated genomic DNA as described, 6 and performed nested PCR with two sets of primers, ie ACTGAAGACCAATATTCACTG (5Ј-primer) and AGTAAGCGCTTCATCGCCTCTGCTGTGC (3Ј-primer) for the first amplification, and CATGAATTCGAGAAGACATGGAAT GTTGGAAGCAGC (5Ј-primer) and TGTGAATTCCAAGGGA GGTGTGTTGGTAATGTAGC (3Ј-primer) for the second amplification. The two 5Ј-primers are located in exon 14 of p85␣/PI3-kinase and the two 3Ј-primers are located in exon 15 of p85␣/PI3-kinase. The amplified product had a size of 1.4 kb, consisting of parts of exon 14 and exon 15 and the intron in between, which had a size of 1.1 kb. After subcloning of the PCR products in the PCR II vector (Invitrogen, Carlsbad, CA, USA) individual clones were sequenced with an automated DNA sequence analyzer.
Antibodies
Two monoclonal antibodies (mAb) specific for the ␣-isoform of the p85 subunit of PI3-kinase were obtained from Upstate Biotechnology (Lake Placid, NY, USA). These mAb are directed against polypeptides consisting of amino acids 1-79 of human p85␣ located within the SH3 domain at the amino terminus (Cat. No. 05-212), and amino acids 327-434 of rat p85␣ (N-SH2 domain) (Cat. No. 05-217). A rabbit polyclonal antibody specific for p110␣ (Cat No. sc-7174) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-specific antibodies directed against Akt phosphorylated at serine 473, and antibodies which detect Akt independent of the phosphorylation state were purchased from New England BioLabs (Beverly, MA, USA).
Biochemical analysis
Cells were lysed in NP-40 lysis buffer as described previously, 42 and the cell lysates were stored in liquid nitrogen until used. Cell lysates were immunoprecipitated with the indicated antibodies and the immunoprecipitates were analyzed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) followed by immunoblotting as described. 43, 44 Filters were developed using the ECL system according to the manufacturer (Amersham, Arlington Heights, IL, USA). PI3-kinase activity in anti-p85␣ or anti-phosphotyrosine immonoprecipitates was analyzed by the phosphorylation of phosphatidylinositol with [␥32P]ATP and separation of the extracted phospholipids on thin layer chromatography as described previously. 45 
Results
Expression of an aberrant p85␣/PI3-kinase protein in CO cells
During our analysis of p85␣/PI3-kinase expression in human leukemia and lymphoma cells we detected an aberrant form of the p85␣ subunit of PI3-kinase in a Hodgkin's diseasederived cell line (CO). As shown in Figure 1 , CO cells express a 76 kDa protein (p76␣), which can be detected after immunoblotting with a monoclonal antibody directed against the
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Figure 1
Expression of a mutated p85/PI3-kinase protein of 76 kDa (p76␣) in a Hodgkin's disease-derived cell line (CO). Total cell lysates prepared from peripheral blood mononuclear cells from a healthy donor (PBMC) (lane 1), the Hodgkin's disease-derived cell lines DEV and CO (lanes 2 and 3), and from 10 patients (1-10) with acute myeloid leukemia (lanes 4-13) were separated by SDS-PAGE followed by immunoblotting with a monoclonal antibody directed against the amino terminal SH2 domain of p85␣. The positions of the normal p85␣/PI3-kinase (p85␣) and the truncated p76␣/PI3-kinase (p76␣) bands are indicated. Numbers at the right indicate the position of molecular mass markers in kDa.
N-terminal SH2-domain (N-SH2) of the p85␣ subunit of PI3-kinase ( Figure 1, lane 3) . The expression of p76␣ in CO cells was confirmed using a monoclonal antibody directed against the SH3 domain of p85␣ located at the amino terminus (data not shown). The normal p85␣ protein, which was present in peripheral blood mononuclear cells (PBMC) from a healthy donor ( Figure 1 
Cloning of a mutated p85␣ cDNA from CO cells
To investigate the aberrant p85␣ protein in more detail, we amplified p85␣ cDNAs from CO cells and from control DEV cells by RT-PCR as described in the Materials and methods. Sequence analysis of the primary RT-PCR product of p85␣ from CO cells revealed a point mutation at position 1907 of the open reading frame of p85␣, where one adenine base had been deleted (Figure 2a ). Due to this deletion, the reading frame of p85␣ was shifted after the first 635 amino acids (aa), and 25 new aa were expressed before a stop codon led to premature termination (Figure 2a ). This aberrant protein of 660 aa has a calculated molecular mass of 76 098 kDa. This matched the apparent molecular mass of the p76␣ protein determined by SDS-PAGE (Figure 1, lane 3) . As a result of the premature termination, only 12 out of 97 aa of the C-terminal SH2-domain were present in p76␣. A schematic representation of p76␣ and p85␣ is shown in Figure 2b .
CO cells contain a mutated and a wild-type allele of p85␣
To confirm that the mutation detected in the aberrant cDNA was also present in genomic DNA from CO cells, and to investigate whether CO cells still had a wild-type p85␣ allele, we analyzed genomic clones of p85␣ from CO cells. According to the published genomic structure of murine p85␣ the frame-shift mutation found in p85␣ cDNA in CO cells was located in exon 14 of the p85␣ gene. 46 Therefore, we performed a nested PCR amplification on genomic DNA of CO cells, using primers located in exons 14 and 15 of p85␣. The amplified DNA, which had a size of 1.4 kb and included 1.1 kb from intron 14 was subcloned and sequenced. Two out of five genomic clones of p85␣ from CO cells had the same mutation, ie a deletion of one adenine at position 1907 as we had found in the cDNA, and the other three clones contained the wild-type sequence of p85␣ without the frame-shift mutation (data not shown). DNA sequence analysis of two p85␣ genomic clones from control DEV cells showed no mutation at position 1907. These data indicate that the frameshift mutation identified in the p76␣ cDNA is indeed in the genome of CO cells and that these cells carry a mutated and a wild-type allele of p85␣.
The C-terminal truncated form of p85 (p76) binds to the catalytic subunit of PI3-kinase (p110␣)
Interaction between p85 and the catalytic p110 subunit of PI3-kinase is mediated by the inter-SH2 region of p85, which binds to the amino terminus of p110. 25, 47, 48 To analyze whether the C-terminal truncated form of p85␣ (p76␣) can still interact with p110␣ in CO cells, immunoprecipitation experiments were performed. As shown in Figure 3a , immunoprecipitation of p110␣ from a cell lysate of CO cells resulted in the coprecipitation of p76␣ detected by immunoblotting with anti-p85␣ antibodies (Figure 3a, lane 5) . Cells which Association of p76␣ with an active catalytic subunit of PI3-kinase (p110␣). (a) Total cell lysates (TCL) prepared from DEV, CO and Jurkat cells were analyzed by immunoblotting with anti-p85␣ antibodies either directly (lanes 1-3) , or after immunoprecipitation (IP) with an antibody specific for the ␣ isoform of the catalytic subunit of PI3-kinase (p110␣ (lanes 4-6) . The positions of p85␣, p76␣, and immunoglobulin heavy chain (Ig) are indicated. (b) p76␣ was immunoprecipitated from a cell lysate of CO cells and p76␣ associated lipid kinase activity was measured in an in vitro kinase assay with phosphatidylinositol and [␥ 32 P]-ATP as substrates. The phosphorylated product, ie phosphatidyl-inositolphosphate (PIP) was analyzed by thin layer chromatography and visualized by autoradiography.
express normal p85␣/PI3-kinase, ie DEV and Jurkat were used as controls for the coimmunoprecipitation of p85␣ (Figure 3a , lanes 4 and 6). Anti-p85␣ immunoblotting of total cell lysates from the same cells is shown in Figure 3a , lanes 1-3. The phospholipid kinase activity of p110 associated with p76␣ was demonstrated by immunoprecipitating p76␣ from CO cells and performing a phospholipid kinase assay with phosLeukemia phatidylinositol as substrate (Figure 3b ). From these experiments we conclude that mutated p76␣ is associated with the catalytic subunit of PI3-kinase in vivo and that the p76␣ p110 complex has phospholipid kinase activity in vitro.
PI3-kinase/Akt signaling is constitutively activated in CO cells
We further analyzed whether PI3-kinase is constitutively activated in vivo and triggers downstream mitogenic or anti-apoptotic signaling in CO cells. One of the downstream targets of PI3-Kinase is Akt, which is also named protein kinase B. Akt can regulate cell proliferation and inhibit apoptosis in a variety of cell types including hematopoietic cells. 14, 19, 50 As a result of PI3-kinase activation, Akt is translocated to the plasma membrane by binding to PI3-kinase-generated phosphoinositides, ie PI(3,4,5)P 3 and PI(3,4)P 2 through the Akt pleckstrin homology domain. Thereafter, Akt becomes activated by sequential phosphorylation of threonine 308 and serine 473 by phosphoinositide-dependent kinase (PDK) 1 and an unidentified staurosporine-sensitive kinase, respectively. 51, 52 This process of Akt activation is transient as shown for FCS-stimulated NIH3T3 cells (Figure 4a, lanes 1-4) . Stimulation of starved NIH3T3 cells results in the phosphorylation of Akt at serine 473 as shown with phosphospecific AktSer473 antibodies. However, 2 days later this phosphorylation is almost undetectable. In contrast, we detected constitutive phosphorylation of serine 473 of Akt already in unstimulated CO cells growing in regular medium which is undetectable in proliferating NIH3T3 cells (compare Figure 4a, lanes 1 and  5) . After starvation of CO cells in serum-free medium for 2 days, Akt phosphorylation was only partly reduced and even after culturing the cells for 4 days without serum we still detected phosphorylated Akt (Figure 4a, lanes 5-7) . The same filter was analyzed for expression of the mitogen-activated protein kinases Erk1/Erk2 to show equal loading in each lane (Figure 4a, lanes 1-7) .
To demonstrate that this constitutive phosphorylation of Akt in CO cells was PI3-kinase-dependent we incubated CO cells with the PI3-kinase inhibitor wortmannin. The phosphorylation of serine 473 was completely blocked by incubation of CO cells in the presence of 50 nM wortmannin for 3 days (Figure 4b, lanes 1-3) . The same results were obtained by incubating CO cells with wortmannin for 1 day (data not shown). Immunoblotting with an anti-Akt antibody which recognizes Akt independently of the phosphorylation state revealed similar levels of Akt in the presence or absence of inhibitor (Figure 4b, lanes 1-3) . These data demonstrate that in CO cells Akt is constitutively activated, and that this activation is PI3-kinase-mediated.
Inhibition of PI3-kinase/Akt signaling in CO cells results in a reduction of cell proliferation and induction of apoptosis
Next we analyzed whether the constitutive activation of PI3-kinase/Akt signaling inhibits apoptosis and stimulates proliferation in CO cells. As shown in Figure 5a , treatment of CO cells with the same concentration of wortmannin, ie 50 nM, necessary to abrogate Akt phosphorylation resulted in an increased percentage of apoptotic cells as measured by annexin V staining. In addition, cell proliferation was partly inhibited in a concentration-dependent manner after treat-
Figure 4
Akt is constitutively activated in CO cells and can be inhibited by wortmannin. (a) Left panel, NIH3T3 cells were grown in DMEM medium containing 10% fetal calf serum (FCS) until they reached approximately 80% confluency and then lysed (lanes 1). Sister cultures were starved overnight in 0.5% FCS and lysed either directly (lane 2) or after stimulation with 10% FCS for 10 min (lane 3). A portion of the cultures that were stimulated in 10% FCS for 10 min was incubated for an additional 2 days in 0.5% FCS medium before lysis (lane 4). Total cell lysates were analyzed for phosphorylation of Akt on serine 473 by immunoblotting using anti-Ser 473 phospho-specific antibodies. Right panel, CO cells that were grown in RPMI 1640 medium containing 10% FCS were transferred to medium without FCS and incubated for 2 days (lane 6) or 4 days (lane 7) in the absence of serum. Total cell lysates were prepared and phosphorylation of serine 473 on Akt was analyzed by immunoblotting as described above. After stripping, the same filter was incubated with an antibody against mitogen-activated protein kinase (MAPK) Erk1/2 to demonstrate equal loading in each lane. (b) CO cells were grown in regular medium (lane 1), or in medium containing either 50 nM (lane 2) or 100 nM (lane 3) wortmannin for 3 days. After this time the cells were lysed and the lysates were analyzed by immunoblotting with a phosphospecific antibody reactive with Akt phosphorylated at serine 473 (phospho-Akt Ser-473). The same filter was analyzed by immunoblotting with antibodies that detect Akt independent of its phosphorylation state (Akt).
ment of CO cells with wortmannin (Figure 5b) . Similar results were obtained with the PI3-kinase inhibitor LY294002 at concentrations of 12.5 and 25 M (data not shown). These data indicate that the constitutively activated PI3-kinase/Akt signaling is neccessary for maximal proliferation and inhibition of apoptosis of CO cells.
Figure 5
Effects of the PI3-kinase inhibitor wortmannin on proliferation and apoptosis of CO cells. (a) Apoptosis was analyzed by annexin V-FITC staining of CO cells cultured without or with wortmannin at a concentration of 50 nM or 100 nM. Each bar represents the mean ± standard deviation of three experiments. (b) CO cells were grown in regular medium (circles), or in medium containing either 50 nM (triangles) or 100 nM (squares) wortmannin for 3 days. Cells were counted every day using a Coulter counter. Each data point represents the mean ± standard deviation of three separate cell cultures.
Discussion
In this report we describe a mutated form of the p85␣ subunit of PI3-kinase, which was expressed in a human lymphoma cell line (CO) derived from a patient with Hodgkin's disease. A frame-shift mutation in exon 14 of one allele of the p85␣ gene resulted in premature termination and expression of a Cterminal-truncated p85␣/PI3-kinase (p76␣). As a consequence, there was a loss of 85 out of 97 aa of the C-terminal SH2-domain, including the highly conserved FLVRES motif, which is required for binding of SH2 domains to tyrosinephosphorylated proteins. [53] [54] [55] Therefore, p76␣/PI3-kinase does not have a functional C-terminal SH2-domain.
What could be the biochemical and/or biological function of p76␣/PI3-kinase without a C-terminal SH2-domain? Since the inter-SH2 domain, which mediates binding of the adapter subunit to p110␣ was left intact in p76␣, this truncated protein was still able to associate with the p110␣ catalytic subunit of PI3-kinase. The activity of the p76␣/PI3kinase complex was shown in a phospholipid kinase assay and Akt which is a downstream substrate of PI3-kinase was constitutively phos-phorylated in CO cells. Constitutive phosphorylation of Akt, as well as proliferation and anti-apoptotic signaling were inhibited by two PI3-kinase inhibitors, ie wortmannin and LY294002. Thus, PI3-kinase/Akt-mediated signaling is constitutively activated in CO cells, and this pathway was necessary for maximal proliferation and inhibition of apoptosis in CO cells.
Another mutant of p85␣/PI3-kinase, ie p65␣/PI3-kinase has been cloned from a murine lymphoma cell line induced by X-ray irradiation. 31 Like the p76␣/PI3-kinase described here, p65␣/PI3-kinase did not have a C-terminal SH2 domain and cells expressing p65␣/PI3-kinase showed a constitutive activation of PI3-kinase and Akt. 31 Transgenic mice expressing p65␣/PI3-kinase in T lymphocytes developed an infiltrating lymphoproliferative disorder. 32 This is of special interest with respect to the phenotype of CO cells which resemble immature T cells. 56 Whether mutations in p85␣/PI3-kinase occur in primary human T cell lymphomas or in other hematopoietic malignancies has to be analyzed in further experiments.
An interesting question is how the mutated p85␣ adapter without a C-terminal SH2 domain could activate the catalytic activity of PI3-kinase. p76␣ still has an N-terminal SH2 domain and both the N-and C-terminal SH2 domains of p85␣ bind to the same tyrosine-phosphorylated consensus sequences, ie pYXXM 57 or pYVXV 58 in target proteins. However, the C-SH2 domain has a much higher affinity for these sequences and it has been postulated that the high affinity binding of p85␣/PI3-kinase to tyrosine-phosphorylated receptors is mediated by the C-terminal SH2 domain of p85␣. 59, 60 Thus, binding of the mutant p76␣/PI3-kinase complex to cytoplasmic or receptor tyrosine kinases may not be part of the mechanism by which PI3-kinase/Akt signaling becomes constitutively activated in CO cells. In agreement with this hypothesis we did not detect any tyrosine-phosphorylated proteins associated with p76␣/PI3-kinase and no substantial amounts of PI3-kinase activity in anti-phosphotyrosine immunoprecipitates from CO cells (data not shown).
The activation of PI3-kinase by deletion of the p85␣ C-SH2 domain could be explained by a new mechanism of PI3-kinase activation recently proposed by Yu and coworkers. 61, 62 In this model, binding of the regulatory p85 subunit to the p110␣ catalytic subunit inhibits PI3-kinase activity. However, binding of phosphopeptides to the N-or C-terminal SH2 domains of p85␣ stimulates PI3-kinase, suggesting that the SH2 domains may contribute to inhibition of enzymatic activity. According to this model, the presence of wild-type p85␣ with intact SH2 domains is necessary to keep p110␣ in an inactive conformation. CO cells do not express a wild-type p85␣ protein and the truncated p76␣ does not have a functional Cterminal SH2 domain. It is therefore possible that in CO cells, the absence of wild-type p85␣ causes a disinhibition of PI3-kinase activity and subsequently the constitutive stimulation of PI3-kinase-mediated downstream signaling, ie activation of Akt.
Another example of a C-terminal truncated p85␣-PI3-kinase has been described in a colon carcinoma cell line, ie HCC2998, derived from a human tumor. 63 Interestingly, no normal p85␣ protein was detected in either HCC2998 cells, in CMN-5 cells expressing the p65/PI3-kinase described by Jimenez et al, 31 or in CO cells expressing p76␣/PI3-kinase. Although CMN-5 cells had no wild-type p85␣ allele, CO cells did contain an unmutated second allele of p85␣. We were able to detect cDNAs from the wild-type allele of p85␣ in three out of 10 cDNA clones analyzed, indicating that the p85␣ wild-type allele is expressed on the RNA level. How-ever, expression of p85␣ protein was under the level of detection in CO cells. These data suggest a posttranscriptional mechanism by which the expression of the unmutated p85␣ protein is suppressed in CO cells. The absence of normal p85␣ in all three cases of transformed cells expressing C-terminal-truncated forms of p85␣ offers the possibility that normal p85␣ might behave as a tumor suppressor. This idea has to be tested in further experiments by re-introducing wild-type p85␣ in cells expressing truncated, biologically active forms of p85␣/PI3-kinase.
A high frequency of mutations at chromosome locus 5q12-q13, where p85␣ is located, has been detected in cells from patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 64 Although the analysis of blood cells from 10 patients with AML and of six additional HD-derived cell lines, ie L428, L540, L591, DEV, KMH2 and HDLM2 did not reveal the existence of mutated p85␣ subunits, additional studies are necessary to analyze the frequency of mutated p85␣/PI3-kinase in human AMLs and Hodgkin's disease. Since original tissue from the patient with Hodgkin's disease (CO) was no longer available, we could not determine whether the mutated p85␣ allele was present in the H/RS cells in the original tissue sample from which the CO cell line has been established. Therefore, we can not rule out the possibility that this mutation has occurred during cell culture. Nevertheless, the identification of p76␣/PI3-kinase is to our knowledge the first report of a mutated form of the p85␣ regulatory subunit of PI3-kinase in human hematopoietic cells and may reflect other instances of mutational activation of p85␣/PI3-kinase in hematopoietic malignancies.
